TWI863003B - 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途 - Google Patents

經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途 Download PDF

Info

Publication number
TWI863003B
TWI863003B TW111139090A TW111139090A TWI863003B TW I863003 B TWI863003 B TW I863003B TW 111139090 A TW111139090 A TW 111139090A TW 111139090 A TW111139090 A TW 111139090A TW I863003 B TWI863003 B TW I863003B
Authority
TW
Taiwan
Prior art keywords
alkyl
group
independently selected
halogen
pyrazolo
Prior art date
Application number
TW111139090A
Other languages
English (en)
Chinese (zh)
Other versions
TW202317567A (zh
Inventor
魯本 阿巴揚
奧列格 米特金
弗拉迪斯拉夫 澤諾諾維奇 帕欽斯基
阿列克謝 普什尼科夫
亞歷山大 瓦西裡耶維奇 伊瓦奇琴科
尼古拉 薩楚克
Original Assignee
美商洛蒙治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商洛蒙治療公司 filed Critical 美商洛蒙治療公司
Publication of TW202317567A publication Critical patent/TW202317567A/zh
Application granted granted Critical
Publication of TWI863003B publication Critical patent/TWI863003B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111139090A 2021-10-15 2022-10-14 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途 TWI863003B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
US63256260 2021-10-15

Publications (2)

Publication Number Publication Date
TW202317567A TW202317567A (zh) 2023-05-01
TWI863003B true TWI863003B (zh) 2024-11-21

Family

ID=85988576

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111139090A TWI863003B (zh) 2021-10-15 2022-10-14 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途
TW113124708A TW202442645A (zh) 2021-10-15 2022-10-14 經取代的１Ｈ－吡唑并［４，３－ｃ］喹啉、製備方法及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113124708A TW202442645A (zh) 2021-10-15 2022-10-14 經取代的１Ｈ－吡唑并［４，３－ｃ］喹啉、製備方法及其用途

Country Status (11)

Country Link
US (1) US20250011319A1 (enExample)
EP (1) EP4416146A4 (enExample)
JP (1) JP2024539633A (enExample)
KR (1) KR20240093606A (enExample)
CN (1) CN118076605A (enExample)
AU (1) AU2022364646B2 (enExample)
CA (1) CA3233233A1 (enExample)
MX (1) MX2024004569A (enExample)
TW (2) TWI863003B (enExample)
WO (1) WO2023064133A1 (enExample)
ZA (1) ZA202406375B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
US20200190104A1 (en) * 2015-06-25 2020-06-18 University Health Network Hpk1 inhibitors and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486264B2 (en) * 2019-03-26 2025-12-02 Janssen Pharmaceutica Nv Bicyclic HPK1 inhibitors
US20210269434A1 (en) * 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
US20200190104A1 (en) * 2015-06-25 2020-06-18 University Health Network Hpk1 inhibitors and methods of using same

Also Published As

Publication number Publication date
AU2022364646B2 (en) 2025-10-09
EP4416146A1 (en) 2024-08-21
ZA202406375B (en) 2025-01-29
CA3233233A1 (en) 2023-04-20
AU2022364646A1 (en) 2024-03-28
CN118076605A (zh) 2024-05-24
JP2024539633A (ja) 2024-10-29
TW202317567A (zh) 2023-05-01
TW202442645A (zh) 2024-11-01
MX2024004569A (es) 2024-04-30
US20250011319A1 (en) 2025-01-09
WO2023064133A1 (en) 2023-04-20
EP4416146A4 (en) 2025-11-05
KR20240093606A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
JP6775645B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
KR102815634B1 (ko) 면역조절제로서 복소환형 화합물
CN108473495B (zh) 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
JP6549311B2 (ja) インドール誘導体、その調製方法および医薬におけるその使用
CN117157292A (zh) Kras g12d抑制剂和其用途
WO2022192745A1 (en) Mta-cooperative prmt5 inhibitors
CA2848604C (en) Viral replication inhibitors
AU2017376629A1 (en) Benzimidazole compounds as c-Kit inhibitors
TW201835067A (zh) 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP2010522765A (ja) 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
KR20030070050A (ko) 헤테로시클릭 에테르 치환 이미다조퀴놀린
CN104837832A (zh) Gdf-8抑制剂
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
KR20180052702A (ko) Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체
KR20170075756A (ko) 카르바졸 유도체
JP2021527654A (ja) Ｍａｌｔ１阻害剤としてのピラゾール誘導体
WO2014079364A1 (zh) 咪唑酮类衍生物、其药物组合物和用途
TW202339721A (zh) Bcl-xL抑制劑
CN104507945A (zh) 作为syk抑制剂的吡咯并[2,3-b]吡嗪
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
TWI863003B (zh) 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途
CN113891880A (zh) 作为吲哚胺2,3-双加氧酶的选择性抑制剂的酰胺取代的咪唑并化合物
JP2023539526A (ja) インターフェロン遺伝子刺激因子ｓｔｉｎｇのアゴニスト
JP7710756B2 (ja) Ｃｔｌａ－４低分子分解剤及びその使用
CN115003383B (zh) 干扰素基因刺激物sting的双环激动剂